Last reviewed · How we verify
Insulins
Insulins is a Small molecule drug developed by Canadian Network for Observational Drug Effect Studies, CNODES. It is currently in Phase 2 development. Also known as: insulins and analogues for injection, fast-acting, insulins and analogues for injection, intermediate-acting, insulins and analogues for injection, long-acting, insulins and analogues for inhalation.
Insulin is a peptide hormone that regulates the metabolism of carbohydrates, fats, and protein by promoting the absorption of glucose from the blood into cells. It acts as an insulin receptor agonist, binding to the insulin receptor to facilitate glucose uptake in the body.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Insulins |
|---|---|
| Also known as | insulins and analogues for injection, fast-acting, insulins and analogues for injection, intermediate-acting, insulins and analogues for injection, long-acting, insulins and analogues for inhalation |
| Sponsor | Canadian Network for Observational Drug Effect Studies, CNODES |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Text Message for Adolescents With Poorly Controlled Type 1 Diabetes (NA)
- Epigenetic Regulation of Human Adipose Tissue Distribution (NA)
- Sleep Loss and Circadian Misalignment - Mechanisms of Insulin Resistance (PHASE4)
- Trial of the Combination of Alpha-Lipoic Acid and Mirabegron in Women and in Men With Obesity (PHASE2)
- Risk Assessment of Pancreatic Islet Autoimmunity in Patients With AITD
- Assessments of Adipogenesis, Lipid Turnover and Cellular Composition in Adipose Tissue in Response to Endurance Exercise (NA)
- Critical Food Ingredients on Immunocompetence to Prevent the Risk and Development of Obesity/Metabolic Syndrome (NA)
- Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Insulins CI brief — competitive landscape report
- Insulins updates RSS · CI watch RSS
- Canadian Network for Observational Drug Effect Studies, CNODES portfolio CI
Frequently asked questions about Insulins
What is Insulins?
Who makes Insulins?
Is Insulins also known as anything else?
What development phase is Insulins in?
Related
- Manufacturer: Canadian Network for Observational Drug Effect Studies, CNODES — full pipeline
- Therapeutic area: All drugs in Metabolic
- Also known as: insulins and analogues for injection, fast-acting, insulins and analogues for injection, intermediate-acting, insulins and analogues for injection, long-acting, insulins and analogues for inhalation
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing